🔬 Latest pharma industry updates 👇
💉 The Lancet Group study reported vaccines saved 154M lives since 1974, countering rising antivax sentiment; most were children under 5.
🤝 Sanofi paid $125M upfront (up to $1.72B total) to Earendil Labs for 2 autoimmune and inflammatory bowel disease bispecific antibody drugs.
⚠️ Trump administration proposed 19% FDA budget cuts, risking agency's ability to fulfill regulatory duties.
🧠 Exciting Parkinson’s research published in Nature Magazine showed safe transplantation of stem cell-derived dopamine-producing neurons with promising symptom improvement in early studies.
💊 Eli Lilly and Company’s oral diabetes and obesity pill orforglipron succeeded in Phase 3, reducing blood sugar and body weight, competing with injectable GLP-1 treatments.
🐁 FDA historic shift announced to replace animal tests with AI and “organ-on-a-chip” methods, shaking up drug development practices, supported by animal advocates.
📈 Recursion stock rose 28% due to FDA’s animal testing reduction policy.
🚫 Pfizer discontinued obesity pill danuglipron after a potential liver damage case, a significant setback in its obesity market ambitions.
📊 Johnson & Johnson raised annual sales forecast after strong Q1 (+2.4%), confident despite Trump's tariffs impacting pharmaceuticals.
💰 Glycomine Inc. secured $115M to advance clinical testing for drug treating rare glycosylation disorders.
🧬 Verve Therapeutics’ gene-editing cholesterol treatment safely lowered cholesterol in small trial after earlier setback, potentially offering lifelong heart attack prevention.
❌ Third Harmonic Bio winding down, selling assets due to financial constraints after disappointing immune-drug results.
🌐 World Health Organization delegates reached a preliminary agreement on a pandemic treaty addressing tech transfer and pathogen data sharing.
📈 Eli Lilly and Company’s Mounjaro® launch in India creates huge demand for affordable obesity treatment, pressuring Novo Nordisk to accelerate Wegovy®’s entry.
❌ Mural Oncology shares down 134% after halting nemvaleukin alfa clinical trials, planning a strategic sale, and reducing workforce by 90%.
💊 Trump signed an executive order to extend Medicare drug price negotiation timelines, aligning small molecules with biologics (13-year exclusivity), yet paradoxically encouraging drug importation.
❌ Bristol Myers Squibb’s heart drug Camzyos failed a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy.
🤝 Ligand Pharmaceuticals and Channel Therapeutics merged to form Pelthos Therapeutics, receiving $50M investment.
🔬 Trump's $2.26B Harvard University funding cuts forced research stoppage on TB, ALS, and radiation biology, risking serious healthcare implications.
⚠️ European Medicines Agency warned of fragile radiopharmaceutical supply chains, urging stronger EU production.